U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday. Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) fell sharply during Wednesday’s session after the company announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.Iovance Biotherapeutics shares dipped 20.4% to $7.07 on Wed…

Read More